Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2004

View Archived Issues

Nabi remains on track to achieve key 2004 milestones

Antitumor efficacy of ABX-EGF in metastatic renal cancer

Preoperative gabapentin reduces the need for analgesics following vaginal hysterectomy

ChemDiv and Yale University receive STTR grant

ViroPharma sells biodefense assets for antiviral drug to SIGA Technologies

Thiophene-based PPARdelta agonist with high potency and selectivity

Safe and effective new antiasthmatic agent, OS-0217, characterized at ACS meeting

Results from Thelin and Viagra drug-drug interaction study

Biovail, Schering-Plough terminate Cedax agreement, Shionogi takes rights

Orphan drug designation for AGRO-100

Sankyo and Fujisawa terminate agreements for CS-758

Novel DPP-IV inhibitors developed at Merck & Co.

Merck scientists identify new cannabinoid CB1 modulators for obesity and other uses

New modulators of chemokine CCXCKR2 receptors and their use in cancer therapy

New factor Xa inhibitors in early development at Lilly

Modulators of PDE4, MMP and/or TNF-alpha discovered at Celgene

Novel tryptase inhibitor covered by Aventis patent

Amgen claims CDK inhibitors and their use

PEP-005 initiates human clinical trials

Biovitrum acquires oncology project from Karolinska

Ark signs marketing agreement with Teva for Keraboot in Israel

Johnson & Johnson to acquire Biapharm

SPA agreement for pivotal studies of Corlux

Approvable letter for Certican

New integrin receptor antagonists presented at the recent ACS meeting

New-generation antibiotics show efficacy against burn wound infections

Favorable properties described for Neuropharma's novel thiazolidinediones

Positive new phase II results for Liprostin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...